

**Table S4. Post-vaccination immunogenicity for participants aged 24–35 months**

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
HAI GMT	A(H1N1)	246	410 (351–478)	246	488 (418–569)	1.19 (0.957–1.48) <sup>a</sup>
	A(H3N2)	248	400 (322–498)	246	608 (500–741)	1.52 (1.13–2.04) <sup>a</sup>
	B/Victoria	246	460 (388–544)	246	611 (521–716)	1.33 (1.05–1.67) <sup>a</sup>
	B/Yamagata	247	428 (363–505)	247	577 (487–683)	1.35 (1.06–1.70) <sup>a</sup>
Seroconversion rate (%)	A(H1N1)	225	84.4 (79.0–88.9)	231	87.0 (82.0–91.1)	2.6 (–3.89–9.06) <sup>b</sup>
	A(H3N2)	227	82.8 (77.3–87.5)	232	82.8 (77.3–87.4)	–0.1 (–6.98–6.89) <sup>b</sup>
	B/Victoria	225	92.4 (88.2–95.5)	231	95.2 (91.6–97.6)	2.8 (–1.73–7.49) <sup>b</sup>
	B/Yamagata	226	92.5 (88.2–95.6)	234	95.7 (92.3–97.9)	3.2 (–1.15–7.87) <sup>b</sup>
Post- to pre- vaccination GMT ratio	A(H1N1)	225	11.1 (9.47–12.9)	231	15.5 (13.2–18.2)	-
	A(H3N2)	227	11.6 (9.65–14.0)	232	14.5 (12.0–17.5)	-

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
	B/Victoria	225	13.3 (11.5–15.3)	231	19.7 (17.2–22.7)	-
	B/Yamagata	226	14.2 (12.4–16.4)	234	22.3 (19.3–25.6)	-

Immunogenicity was assessed according to the vaccine received in all participants in the immunogenicity subset who received at least one dose of the study vaccine, had a valid post-vaccination serology result for at least one strain, and completed the study according to protocol. Abbreviations: CI, confidence interval; GMT, geometric mean titer; HAI, hemagglutination inhibition; IIV4, quadrivalent split-virion inactivated influenza vaccine; -, not calculated/determined.

<sup>a</sup> Ratio of HAI GMTs (full dose/half dose).

<sup>b</sup> Difference in seroconversion rate: seroconversion rate for the full dose of IIV4 minus the seroconversion rate for the half dose of IIV4.